TLD-1433 is under clinical development by Theralase Technologies and currently in Phase II for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). According to GlobalData, Phase II drugs for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TLD-1433’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TLD-1433 overview
TLD-1433 is under development for the treatment of non-muscle invasive bladder cancer, non-small cell lung cancer, glioblastoma multiforme, coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and herpes simplex virus. It is a photodynamic therapeutic candidate. The drug candidate is administered through intravesical, intravenous and parenteral route. It is being developed based on photodynamic platform technology and enhanced radiation therapy platform technology.
It was also under development for the treatment of oropharyngeal cancer, colon cancer and cervical cancer.
Theralase Technologies overview
Theralase Technologies (Theralase) is a clinical-stage pharmaceutical company that specializes in the design, development and manufacturing of laser based technologies used in a wide range of bio-destructive and bio-simulative clinical applications. It focused on the development of laser-based non-invasive therapeutic devices (laser systems) used for the reduction of chronic knee pain, inflammation, and accelerate tissue healing for numerous nerve, muscle, and joint conditions. The company photo dynamic therapy is dedicated to the discovery and development of small, light-activated photodynamic compounds (PDC’s) and their associated drug formulations based on its proprietary non-immunosuppressive photodynamic technology targeting cancer cells, bacterial infections, and promotes microbial sterilization. Theralase supplies its products through a network of distributors in Canada, the US and internationally. Theralase Technologies is headquartered in Toronto, Ontario, Canada.
For a complete picture of TLD-1433’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
